Myeloma

2025: Using a new blood cancer treatment that holds back cancer cell development three times longer than conventional therapy

In mid-June 2025, it became known that Britain's National Health Service she began to use a new cancer treatment blood method, which three times longer restrains the development of malignant than formations traditional approaches. The technology is called "Trojan Horse" therapy.

The proposed method is aimed at combating myeloma: in this disease, excessive reproduction of plasma cells and an increase in the level of specific immunoglobulins occurs. This malignant formation affects the bone marrow and the bones themselves, as well as negatively affects the patient's immunity. Usually, radiation or chemotherapy is used in the treatment of myeloma.

𝓲

Фото: Freepik

The new technology was developed by GSK in Britain. Early research was carried out in Stevenage and the first clinical trials in London. The "Trojan horse" method is an advanced form of chemotherapy that allows cancer cells to be targeted with higher efficacy while reducing side effects. The essence of the technology is that the chemotherapeutic drug binds to antibodies, which then detect cancer cells by special markers and penetrate them. Next, the drug is released, which leads to the death of tumor cells.

This therapy does not allow to cure myeloma completely. However, it is able to stop the development of blood cancer for three years, compared with 13 months when using other modern treatments. It is also said that the new therapy is more gentle than other cancer treatments, but not devoid of side effects. After the destruction of tumor cells, the remains of the chemotherapeutic drug enter the body. This can cause, in particular, dry eyes and blurred vision.^[1]

2023: The production of drugs for the treatment of myeloma has begun in the SEZ "St. Petersburg." 20 billion rubles invested in it

Pharmasintez-Nord has released at its enterprise, which is located in the special economic zone (SEZ) "St. Petersburg," the first batch of the drug with the active substance for the therapy of multiple myeloma. This was reported in the group in early October 2023. Read more here.

Notes